Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI) (Q26825591)

Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Anticonvulsive effects of galanin administered into the central nervous system upon the picrotoxin-kindled seizure syndrome in rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Benzodiazepines on trial: a research strategy for their rehabilitation

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Galanin reduces release of endogeneous excitatory amino acids in the rat hippocampus

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Chemical properties of antiepileptic drugs (AEDs).

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

The role of cytokines in the pathophysiology of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX).

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Brivaracetam (ucb 34714) inhibits Na(+) current in rat cortical neurons in culture.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X).

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Behavioral, cognitive, and safety profile of 2-deoxy-2-glucose (2DG) in adult rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Interleukin Converting Enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1beta production

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Regulation of limbic status epilepticus by hippocampal galanin type 1 and type 2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

The galanin peptide family in inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Valproic Acid: second generation

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Developing novel antiepileptic drugs: characterization of NAX 5055, a systemically-active galanin analog, in epilepsy models

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Neurosteroid modulation of synaptic and extrasynaptic GABAA receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Chronic ingestion of 2-deoxy-D-glucose induces cardiac vacuolization and increases mortality in rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

The effects of pharmacological doses of 2-deoxyglucose on cerebral blood flow in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Evaluation of the novel antiepileptic drug, AWD 131-138, for benzodiazepine-like discriminative stimulus and reinforcing effects in squirrel monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

An update on GABAA receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

The antiepileptic drug AWD 131-138 stimulates different recombinant isoforms of the rat GABA(A) receptor through the benzodiazepine binding site

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V).

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Development of new antiepileptic drugs: challenges, incentives, and recent advances

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Differential expression of connexins in trigeminal ganglion neurons and satellite glial cells in response to chronic or acute joint inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

2-Deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Key factors in the discovery and development of new antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

The neurobiology of antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Pharmacokinetics of anti-epileptic drugs in the dog: a review

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Tonabersat inhibits trigeminal ganglion neuronal-satellite glial cell signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Anticonvulsant and proconvulsant actions of 2-deoxy-D-glucose

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Tolerability and safety of perampanel: two randomized dose-escalation studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Regulation of kindling epileptogenesis by hippocampal galanin type 1 and type 2 receptors: The effects of subtype-selective agonists and the role of G-protein-mediated signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Brivaracetam disposition in renal impairment

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Effect of brivaracetam on cardiac repolarisation--a thorough QT study

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Modulation of hippocampal excitability and seizures by galanin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

The second galanin receptor GalR2 plays a key role in neurite outgrowth from adult sensory neurons

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EPLEPSYRES.2012.10.001

7 January 2021

10.1016/J.EPLEPSYRES.2012.10.001

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

23219031

1 reference

Consolidated OpenCitations Corpus – April 2017